A Phase 1b, 2-part, placebo-controlled study to evaluate the efficacy, safety, and PK of PF-07054894 in participants with mild to severe UC.

2022-501047-32-00 Protocol C4151002 Human pharmacology (Phase I) - Other Ended

Start 30 May 2023 · End 11 Nov 2025 · Status Ended · 2 EU/EEA countries · 12 sites · Protocol C4151002

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 48
Countries 2
Sites 12

ULCERATIVE COLITIS

Key facts

Sponsor
Pfizer Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Digestive System Diseases [C06]
Trial duration
30 May 2023 → 11 Nov 2025
Decision date (initial)
2023-03-14
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2022-501047-32-00
ClinicalTrials.gov
NCT05549323

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

ULCERATIVE COLITIS

VersionLevelCodeTermSystem organ class
20.1 LLT 10045365 Ulcerative colitis 10017947

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Pfizer Inc.

Sponsor organisation
Pfizer Inc.
Address
66 Hudson Boulevard East
City
New York
Postcode
10001-2189
Country
United States

Scientific contact point

Organisation
Pfizer Inc.
Contact name
Clinical Medical Lead

Public contact point

Organisation
Pfizer Inc.
Contact name
Clinical Medical Lead

Locations

2 EU/EEA countries · 12 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ended 16 1
Poland Ended 19 11
Rest of world
United States
13

Investigational sites

Germany

1 site · Ended
Charite Research Organisation GmbH
Medical Operations, Chariteplatz 1, Mitte, Berlin

Poland

11 sites · Ended
Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki W Krakowie
Zakład Endoskopii NSSU, Ul. Macieja Jakubowskiego 2, 30-688, Krakow
Medical Network Sp. z o.o.
WIP Warsaw IBD Point Profesor Kierkus, Ul. Plowiecka 103, 04-501, Warsaw
Centrum Medyczne Kermed Renata Bijata-Bronisz I Ewa Kowalinska Sp. j.
-, Ul. Krolowej Jadwigi 16, 85-231, Bydgoszcz
Klimed MK Sp. z o.o.
-, Aleja Jana Pawla II 59/6u, 15-704, Bialystok
Irmed Klimkiewicz Rudziewicz-Kowalska sp. j.
-, Ul. Polskiej Organizacji Wojskowej 12 C, 97-300, Piotrkow Trybunalski
Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy
Klinika Gastroenterologii i Chorob Wewnetrznych, Ulica Szaserow 128, 04-141, Warsaw
Med Sp. z o.o.
-, Ul. Polnej Rozy 6/u2, 02-798, Warsaw
Niepubliczny Zaklad Opieki Zdrowotnej Twoje Zdrowie El Sp. z o.o.
Ul. Elizy Orzeszkowej 13, Ul. Elizy Orzeszkowej 13, 82-300, Elblag
Centrum Medyczne Med-Gastr Sp. z o.o.
-, Ul. Mokra 4, 91-034, Lodz
Mz Badania Slowik Zymla Sp. j.
-, Ul. Ks. Alojzego Kozielka 8, 44-190, Knurow
H-T.Centrum Medyczne Sp. z o.o. sp.k.
-, Aleja Bielska 105, 43-100, Tychy

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2023-07-04 2025-10-24 2023-08-08 2025-09-15
Poland 2023-05-30 2025-11-05 2023-06-20 2025-09-15

Application history

14 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2022-11-15 Germany Acceptable
2023-03-13
2023-03-14
2 NON SUBSTANTIAL MODIFICATION NSM-2 2023-03-23 Germany Acceptable
2023-03-13
2023-03-23
3 SUBSTANTIAL MODIFICATION SM-2 2023-04-04 Acceptable 2023-05-22
4 SUBSTANTIAL MODIFICATION SM-1 2023-04-12 Germany Acceptable 2023-05-02
5 SUBSTANTIAL MODIFICATION SM-3 2023-07-05 Germany Acceptable 2023-07-20
6 SUBSTANTIAL MODIFICATION SM-4 2023-08-18 Germany Acceptable
2023-10-19
2023-10-23
7 NON SUBSTANTIAL MODIFICATION NSM-3 2023-11-27 Acceptable
2023-10-19
2023-11-27
8 NON SUBSTANTIAL MODIFICATION NSM-4 2024-04-15 Germany Acceptable
2023-10-19
2024-04-15
9 SUBSTANTIAL MODIFICATION SM-5 2024-04-26 Acceptable 2024-06-14
10 SUBSTANTIAL MODIFICATION SM-6 2024-08-15 Germany Acceptable
2024-10-09
2024-10-10
11 NON SUBSTANTIAL MODIFICATION NSM-5 2024-10-17 Germany Acceptable
2024-10-09
2024-10-17
12 NON SUBSTANTIAL MODIFICATION NSM-6 2024-10-29 Germany Acceptable
2024-10-09
2024-10-29
13 SUBSTANTIAL MODIFICATION SM-7 2025-03-04 Germany Acceptable
2025-04-16
2025-04-22
14 NON SUBSTANTIAL MODIFICATION NSM-7 2025-10-08 Germany Acceptable
2025-04-16
2025-10-08